MedTrace Logo

A Survey on Efficacy and Safety in Patients With Endometriosis

NCT02921763 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2022-07-06

Study results available
· View outcomes & findings →

Summary

This survey is intended to collect efficacy and safety data of Duphaston® Tablets in patients with endometriosis under actual condition of its use and to obtain data for effectively and safely utilizing this drug.

Conditions

  • Endometriosis

Interventions

DRUG

Dydrogesterone

Sponsors & Collaborators

  • Mylan Inc.

    lead INDUSTRY

Principal Investigators

  • Jo Kitawaki, MD., PhD. · Kyoto Prefectural University of Medicine

Eligibility

Min Age
20 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-23
Primary Completion
2017-09-21
Completion
2017-10-13

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02921763 on ClinicalTrials.gov